Pharmacy

Your Article Summary

See Latest Articles

Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
Active Biotech, 06/26/09

Teva Pharmaceutical Industries Ltd. and Active Biotech announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis. BRAVO is a global clinical trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
BMC Infectious Diseases, 12/03/09

Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

 See all of Drug Trials

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

An Updated Focused Review of Dexmedetomidine in Adults
Annals of Pharmacotherapy, 12/03/09

Psychotropic Medication Changes, Polypharmacy, and the Risk of Early Readmission in Suicidal Adolescent Inpatients
Annals of Pharmacotherapy, 12/03/09

Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study
American Journal of Alzheimer's Disease and Other Dementias, 12/02/09

 See all of Neuro/Psych pharmacology